Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 4/20 | 0.70 |
| ▸ | CA2 | P00918 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11037223 | 0.98 | PLK1 (0.96) | PLK1SMN1; SMN2HPGDTSHRHTT | |
| SCHEMBL14722006 | 0.94 | PLK1 (0.89) | PLK1SMN1; SMN2HPGDTSHRHTT | |
| SCHEMBL23484773 | 0.94 | PLK1 (0.89) | PLK1SMN1; SMN2HPGDTSHRHTT | |
| Phosphonic Acid SCHEMBL1060959 | 0.92 | PLK1 (0.85) | PLK1SMN1; SMN2HPGDTSHRHTT | |
| SCHEMBL8717056 | 0.89 | PLK1 (0.80) | PLK1SMN1; SMN2HTTCA1CA2 | |
| SCHEMBL5582971 | 0.86 | PLK1 (0.74) | PLK1SMN1; SMN2HPGDTSHRHTT | |
| SCHEMBL4754917 | 0.85 | ALDH1A1 (0.78) | PLK1SMN1; SMN2HTTCA1CA2 | |
| SCHEMBL11705060 | 0.84 | MAPT (0.79) | PLK1SMN1; SMN2HPGDCA1CA2 | |
| SCHEMBL2645679 | 0.84 | HPGD (0.76) | PLK1SMN1; SMN2HPGDTSHRHTT | |
| SCHEMBL13184545 | 0.84 | HPGD (1.00) | PLK1SMN1; SMN2HPGDTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | claimed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | claimed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025151449-A1 | BIFUNCTIONAL P53-BINDING COMPOUNDS AND USES THEREOF | PHOTYS THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025085725-A1 | METHODS FOR TREATING A P53-ASSOCIATED CANCER | SCORPION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024238404-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-3989704-A | 3-Substituted-4-aryl isoquinolines | SANDOZ, INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3959269-A | TRANQUILIZERS, SEDATIVES | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3944570-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | PLK1 3051/4885SMN1; SMN2 4646/4885HPGD 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.